{"id":"sustained-release-oral-dalfampridine","safety":{"commonSideEffects":[{"rate":"0.5-1","effect":"Seizures"},{"rate":"10-15","effect":"Urinary tract infection"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nausea"},{"rate":"3-5","effect":"Asthenia/fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalfampridine blocks voltage-gated potassium channels, which slows repolarization of nerve membranes and allows action potentials to propagate more effectively across demyelinated axons in multiple sclerosis. This mechanism improves nerve conduction velocity and can restore some motor function in MS patients with walking impairment. The sustained-release formulation allows for twice-daily dosing with improved tolerability.","oneSentence":"Dalfampridine is a potassium channel blocker that enhances action potential conduction in demyelinated nerve fibers by prolonging the duration of the action potential.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:16.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis with walking impairment (marketed as Ampyra/Fampyra)"}]},"trialDetails":[{"nctId":"NCT00127530","phase":"PHASE3","title":"Study of Oral Fampridine-SR in Multiple Sclerosis","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2005-05","conditions":"Multiple Sclerosis","enrollment":300},{"nctId":"NCT01683838","phase":"PHASE3","title":"Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2002-06","conditions":"Spinal Cord Injury, Muscle Spasticity","enrollment":204},{"nctId":"NCT02259361","phase":"PHASE4","title":"Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2014-11","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT01235221","phase":"PHASE3","title":"Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-12","conditions":"Multiple Sclerosis","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prolonged-release Fampridine","Ampyra"],"phase":"marketed","status":"active","brandName":"Sustained-release oral dalfampridine","genericName":"Sustained-release oral dalfampridine","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalfampridine is a potassium channel blocker that enhances action potential conduction in demyelinated nerve fibers by prolonging the duration of the action potential. Used for Multiple sclerosis with walking impairment (marketed as Ampyra/Fampyra).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}